Analysts remain bullish on Vertex Pharmaceuticals as HC Wainwright reaffirmed its buy rating with a $550 price target.

Researchers at Vertex Pharmaceuticals in Boston say a single infusion of stem cell-based treatment could be a permanent ...

This was the stock's second consecutive day of gains.

Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) is one of the best biotech stocks to invest in now. On June 20, Vertex ...

Ten people have been effectively cured of their type 1 diabetes after a breakthrough infusion of a new treatment on the path ...

TUESDAY, June 24, 2025 (HealthDay News) — A single infusion of a new stem cell-based treatment may have helped 10 out of 12 ...

Drug company shares are down amid President Donald Trump’s assault on the industry, but some in Congress see value.

Congressional lawmakers are trading millions in pharmaceutical stocks as the Trump administration vies to overhaul the ...

Good morning! Today, we get deeper into the ousting of Nicole Verdun at the FDA, see promise from Vertex’s cell therapy for ...

A study may have found a cure for type 1 diabetes. Here, experts explain how the treatment, zimislecel, works and what it ...

Royalty Pharma will provide up to $1.25 billion in exchange for a synthetic royalty on annual worldwide net sales of daraxonrasib (and zoldonrasib if approved in an overlapping daraxonrasib indication ...